7 Stocks With Up to 3,000% Profit Growth in 2026 Across Pharma, IT, Capital Goods, Infrastructure & More

India Inc. delivered one of its strongest earnings seasons in recent years, with several companies reporting exceptional year on year profit growth driven by robust execution, improving operating margins, higher demand, and business expansion. While some companies benefited from turnaround stories, others continued to post strong earnings backed by sustainable growth across pharmaceuticals, capital goods, infrastructure, information technology, and consumer sectors.

However, investors should look beyond headline profit numbers. Companies where earnings growth is supported by higher revenue, improving margins, healthy order books, and strong return ratios generally offer better long-term investment opportunities than businesses reporting one-off gains or accounting-driven profits.

Based on the latest publicly available quarterly results, company filings, investor presentations, and market data available up to 30 June 2026, here are seven Indian stocks that reported profit growth ranging from double digits to over 3,000% YoY, along with their latest financial metrics and business outlook.

Company	Sector	Profit Growth	CMP (₹)	Market Cap (₹ Cr)	P/E	ROE	Investment View
Laurus Labs	Pharma/CDMO	Strong Growth	1,518	81,977	91.7	18%	Strong Long-Term Growth
GE Power India	Capital Goods	400%+	911	6,124	17.5	77.7%	Turnaround Story
Grasim Industries	Diversified	28%	3,100	2,10,962	41.6	5.05%	Core Portfolio
Tata Consultancy Services	IT Services	12%	2,032	7,35,014	14	52%+	Large-Cap Compounder
Eveready Industries	Consumer	790%+	368	2,671	18.2	27%	Emerging Turnaround
Neuland Laboratories	Pharma/API	650%+	18,579	18,579	65.5	21.4%	Premium Growth
WPIL	Infrastructure	3,000%+	490	4,781	30.2	10.7%	Order Book Driven Growth

Laurus Labs

Laurus Labs continues to be one of the strongest pharmaceutical growth stories in India, supported by rapid expansion of its CDMO business, higher operating leverage, improving product mix, and increasing global outsourcing demand. The company is also investing nearly ₹3,000 crore over the next two years to expand manufacturing capacity, positioning itself for sustained earnings growth.

Key Metrics	Value
Sector	Pharma/CDMO
Profit Trend	Strong Growth
CMP	₹1,518
Market Cap	₹81,977 Cr
P/E	91.7x
ROE	18%
ROCE	20%
Investment View	High-Quality Pharma Growth

GE Power India

GE Power India delivered one of the biggest turnaround performances this earnings season, with quarterly profit rising more than 400% year on year. The improvement was driven by faster project execution, margin recovery, and rising investments in India's power transmission and grid modernization projects.

Key Metrics	Value
Sector	Capital Goods
Profit Growth	400%+
CMP	₹911
Market Cap	₹6,124 Cr
P/E	17.5x
ROE	77.7%
ROCE	80%
Investment View	Strong Turnaround

Grasim Industries

Grasim Industries reported healthy profit growth backed by strong performance across cement, chemicals, paints, financial services, and viscose fibre businesses. The company's diversified business model and continued expansion of Birla Opus Paints support its long-term growth outlook.

Key Metrics	Value
Sector	Diversified
Profit Growth	28%
CMP	₹3,100
Market Cap	₹2,10,962 Cr
P/E	41.6x
ROE	5.05%
Investment View	Diversified Blue Chip

Tata Consultancy Services (TCS)

TCS maintained its consistent earnings trajectory by reporting double-digit profit growth despite global macroeconomic uncertainties. Strong deal wins, healthy margins, zero debt, and industry-leading cash generation continue to make the company one of India's highest-quality large-cap investments.

Key Metrics	Value
Sector	IT Services
Profit Growth	12%
CMP	₹2,032
Market Cap	₹7,35,014 Cr
P/E	14x
ROE	52%+
Investment View	Long-Term Compounder

Eveready Industries

Eveready Industries reported nearly 790% YoY profit growth, reflecting a strong turnaround supported by better operating margins, premium product launches, and improving demand across batteries, flashlights, and consumer appliances.

Key Metrics	Value
Sector	Consumer Goods
Profit Growth	790%+
CMP	₹368
Market Cap	₹2,671 Cr
P/E	18.2x
ROE	27%
ROCE	17%
Investment View	Turnaround Opportunity

Neuland Laboratories

Neuland Laboratories remains one of India's fastest-growing pharmaceutical companies, with profit growing more than 650% YoY. Strong demand for specialty APIs, high-margin CDMO contracts, and robust export growth continue to support earnings expansion.

Key Metrics	Value
Sector	Pharma/API
Profit Growth	650%+
CMP	₹18,579
Market Cap	₹18,579 Cr (use your verified figure)
P/E	65.5x
ROE	21.4%
ROCE	26%+
Investment View	Premium Growth Stock

WPIL

Infrastructure company WPIL reported one of the highest profit growth figures this season, with earnings rising more than 3,000% year on year, supported by execution of its large domestic and international order book. Continued infrastructure spending and healthy project execution remain key growth drivers.

Key Metrics	Value
Sector	Infrastructure
Profit Growth	3,000%+
CMP	₹490
Market Cap	₹4,781 Cr
P/E	30.2x
ROE	10.7%
ROCE	15%
Investment View	Infrastructure Growth Play

Market Analysis

While these companies reported impressive profit growth, the quality of earnings varies significantly. Laurus Labs and Neuland Laboratories continue to benefit from structural growth in the global pharmaceutical and CDMO industry, while GE Power India and WPIL are capitalizing on India's ongoing infrastructure and power sector investment cycle. Grasim Industries offers diversified earnings stability, whereas TCS remains a high-quality compounder with consistent cash generation and shareholder returns. Eveready Industries, meanwhile, represents a turnaround story where operational improvements have translated into sharp earnings growth.

Investors should also evaluate whether profit growth is accompanied by revenue expansion, margin improvement, healthy cash flows, and sustainable return ratios. Companies reporting exceptionally high percentage growth due to a low base effect or one-time exceptional gains may not necessarily deliver similar growth in future quarters. Businesses with strong execution capabilities, healthy order books, and improving fundamentals are generally better positioned for long-term wealth creation.

From a valuation perspective, GE Power India and Eveready Industries trade at relatively reasonable earnings multiples despite strong growth, while Laurus Labs and Neuland Laboratories command premium valuations due to their superior long-term earnings visibility. Investors should balance growth potential with valuation before making investment decisions.

Best Stocks by Investment Theme

Investment Theme	Best Pick
Highest Quality Growth	Laurus Labs
Best Turnaround	GE Power India
Best Large-Cap Compounder	Tata Consultancy Services
Diversified Blue Chip	Grasim Industries
Premium Pharma Growth	Neuland Laboratories
Infrastructure Opportunity	WPIL
Consumer Turnaround	Eveready Industries

Key Risks Investors Should Monitor

Risk Factor	Potential Impact
One-time Profit Gains	May distort earnings growth
Rich Valuations	Limited upside if execution slows
Global Economic Slowdown	Impacts IT and export-oriented companies
Government Capex Slowdown	Affects infrastructure and capital goods companies
Regulatory Changes	Key risk for pharmaceutical companies

Key Takeaways

Highlights	Best Company
Highest Profit Growth	WPIL (3,000%+)
Best Pharma Growth	Laurus Labs
Strongest Turnaround	GE Power India
Most Stable Large Cap	TCS
Best Value Diversified Stock	Grasim Industries
Fastest Consumer Turnaround	Eveready Industries
Premium API Growth	Neuland Laboratories

Which stock reported the highest profit growth?

WPIL reported profit growth of more than 3,000% YoY, making it one of the biggest earnings surprises of FY26.

Which pharma stocks reported strong earnings growth?

Laurus Labs and Neuland Laboratories delivered strong earnings growth backed by expanding CDMO and API businesses.

Which company is the best turnaround story?

GE Power India stands out as one of the strongest turnaround stories due to improved execution, margin recovery, and power sector demand.

Should investors buy stocks solely based on profit growth?

No. Investors should also evaluate revenue growth, operating margins, valuation, cash flows, return ratios, debt levels, and business sustainability before making investment decisions.